#ECTRIMS2024 | Emilio Portaccio outlines the two ways disability accrual occurs in #MultipleSclerosis – relapse-associated worsening (RAW) & progression independent from relapse activity (PIRA).

Click here:
👉 https://buff.ly/4gZeUl3

#MultScler #MS #Neurology #Neuroscience

Natalizumab versus anti-CD20 monoclonal antibodies in the treatment of MS - VJNeurology Maya Zeineddine, PharmD, Lebanese American University, Byblos, Lebanon, discusses the differences between treatment with natalizumab and anti-CD20 monoclonal antibodies in...

Earlier this year, we interviewed Maya Zeineddine to hear about the differences between treatment with natalizumab and anti-CD20 monoclonal antibodies in #MultipleSclerosis.

Watch here:
👉 https://buff.ly/3ZAA42V

#MS #MultScler #ECTRIMS2024 #Neuroscience

Investigating CAR T-cell therapy in the treatment of MS - VJNeurology Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses the potential use of chimeric antigen receptor (CAR) T-cell therapy to...

#CARTCell therapy has revolutionized the treatment of hematological malignancies and is now being considered as a potential treatment for neurological conditions, including #MultipleSclerosis!

Learn more from Krish Patel here:
👉https://buff.ly/3Z7S7MG

#ECTRIMS2024 #MS #MultScler

Investigating evobrutinib and other BTK inhibitors for the treatment of MS - VJNeurology Anneke Van der Walt, PhD, Monash University, Melbourne, Australia, discusses the use of evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor,...

It was a pleasure to interview Anneke Van der Walt, who provided insight into evobrutinib and other BTK inhibitors for the treatment of #MultipleSclerosis.

Click here to watch:
👉 https://buff.ly/3Z8JMbw

#ECTRIMS2024 #MultScler #MS #Neuroscience #Neurology

In an interview from #ECTRIMS2024, Helen Tremlett introduces the concept of a prodromal phase in #MultipleSclerosis and comments on how it has been neglected.

Watch it here:
👉 https://buff.ly/3B1PiVt

#MultScler #MS #Neuroscience #Neurology

Abstract presented at the Ectrims 2024, which rutile is: Temelimab rescues HERV-W mediated neuroinflammatory effects in transgenic mice expressing the envelope protein

Presented yesterday at the #ECTRIMS2024

#MultipleSclerosis has no cure